Curious about Xaira's approach to building better AI for drug discovery?
Curious about Xaira's approach to building better AI for drug discovery?
On the latest episode of the Latent Space podcast, Chief AI Scientist Bo Wang and Chief Discovery Officer Ci Chu discuss their approach to virtual cells, why causal biological datasets matter, and how advances in high-throughput biology are enabling a new generation of predictive AI models.
We are pioneering the transformative artificial intelligence that will help discover and develop the next generation of life-changing medicines.
AI will transform drug discovery by enabling us to make predictions about the right biology to target, the best therapeutic to modulate those targets, and the patients and disease states that will benefit most from those medicines.
We are building predictive and agentic AI models across the complete spectrum of the drug discovery and development process to deliver a pipeline of next generation medicines. We believe the industry must migrate to an engineered approach to delivering therapies to patients that will increase the probability of success, reduce development timelines, and lower costs.
See How
Announcing our first blog post, titled "Progressable Binders: The Binders that Matter"
Read the story
